Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2025 · 10-Q
Revenue$154.99M$154.99M+11.9% vs Q1 2024 Net Income-$34.32M-$34.32MN/M vs Q1 2024 EPS Diluted-$0.31-$0.31N/M vs Q1 2024 Gross Profit$116,473,000+11.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$35,665,000N/M Free Cash Flowderived-$46,276,000N/M Margins · derivedGross margin75.1%−0.5 pt vs Q1 2024
Operating margin-24.4%+5.5 pt vs Q1 2024
Net margin-22.1%+5.8 pt vs Q1 2024
ended Mar 31, 2025 · filed Apr 24, 2025 · 24 d after period end